The most common causes of infertility include deficiencies in semen or egg production such as poor quality and sperm motility, lower hormonal levels, abnormal ejaculation and even psychological conditions. As per Market Research Future (MRFR)’s analysis, the market for infertility stood at 11.2 billion in 2016, and is projected to expand at a CAGR of 4.6 % during the forecast period ending 2023.
Rise In Risk Factors Is The Prime Reason For Market Growth
The increase in risk factors for the global infertility market is sedentary lifestyles, increasing age at marriage, substance abuse, environmental factors, genetic abnormalities, stress, obesity, prostate cancer, varicocele, and others. Smoking, alcohol, anabolic steroid use, and illicit drug use is positively correlated to the growth of infertility. Cancer treatment such as chemotherapy, radiation, also affects fertility. Late marriage and hormonal disorders are other causes associated with infertility. Women infertility is caused by Polycystic ovary syndrome (PCOS), Functional hypothalamic amenorrhea, pelvic infection, ruptured appendicitis, gonorrhea or chlamydia, endometriosis, or abdominal surgery.
Fill Out Details To Receive FREE Sample Here: https://www.marketresearchfuture.com/sample_request/6145
Growth In Awareness and Growing Number of fertility Clinics Is Driving A Large Demand
There has been a keen awareness regarding infertility with concurrent development of fertility clinics. The advent of assisted reproductive techniques has resulted in a significant adoption of these services by the market.
Poor Efficacy of Treatment and High Cost Sssociated May Hamper Market’s Growth
The prime market constraints include the high cost of the procedure, side effects of the drug therapy and social taboos for Infertility treatment and others.
Key players of Global Male Infertility Treatment Market:
Some of the key vendors operating and profiled in the report are Halotech DNA, SCSA Diagnostics, Inc., Andrology Solutions, Zydus Cadila Healthcare Ltd, Androvia LifeSciences, Aetna Inc., Bayer Healthcare, and EMD Serono, Inc.,
To gauge an accurate understanding of the market potentiality, the report is segmented by sex, diagnosis, drugs, techniques, and regions.
Based on the sex, the market is bifurcated as males, females and unexplained.
Based on the diagnosis, the market is bifurcated as men diagnostic tests (semen analysis, genetic testing, testicular biopsy, and other), women diagnostic tests (hysteroscopy, laparoscopy, ovulation testing, hysterosalpingography and others), and general diagnostic tests (genetic testing, hormone testing, microscopic analysis, imaging, and others)
Based on drugs, the market is segmented into clomiphene citrate, letrozole, serophene, hormone treatment and others.
Based on techniques, the market is segmented by assisted reproductive technology (ART), intrauterine insemination, and surgery. The surgery segment is further sub-segmented by laparoscopic or hysteroscopic surgery, tubal surgeries and others.
Based on geography, the market is charted according to North America, Europe, Asia Pacific, Middle East, and Africa.
The US accounts for the maximum market share of the global infertility market attributed to increasing pool of awareness, high income, and good reimbursement scenario. Europe led by Germany, France, and the U.K. is expected to be the second largest market. Advancing technologies within the Infertility treatment is driving the market and will see strategic growth over the next five years. The Asia Pacific, dominated by China, and India is projected to be the fastest growing market owing to a large population with unmet needs and also because the rate of male infertility is highest in South Asia.
According to Centers for Disease Control and Prevention about 6 % of married women ageing 15 to 44 years in the United States are unable to get pregnant after one year of unprotected intercourse. About 12 % of women aged 15 to 44 years in the United States have difficulty getting pregnant or carrying a pregnancy to term. Numerous studies revealed that up to 15 percent of couples are unable to conceive during the first 12 months of unprotected intercourse and about 8 % even after 24 months of unprotected intercourse. Male Infertility treatment accounts for about 50 % of the cases and the reasons for these cannot be determined in about 50 % of cases. About 8 % to 15 % of men suffer from complete lack of sperm. The Centers for Disease Control an
About Market Research Future:
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar